{
  "report_rows": [
    {
      "kpi": "Q2 2026 Diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$11.20 vs. cons $10.40",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$3.05B vs. cons $2.94B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Gross Margin",
      "prediction": "BEAT",
      "answer": "pred ~25.3% vs. cons ~24.7% (implied core level)",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 same-store revenue growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~mid-to-high 20s% (27%) vs. cons ~25% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Book-to-bill / backlog momentum (Q2)",
      "prediction": "LOWER",
      "answer": "guide/implied ~1.1x book-to-bill vs. cons expectation ~1.2x (Q2 2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY2026 gross margin range commentary",
      "prediction": "UNCHANGED",
      "answer": "guide ~25% 'strong range' vs. cons ~24.5% modeled (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.5,
  "day5_path": "FADE",
  "day5_rationale": "Headline beat likely driven by continued backlog conversion and volume, but with Q1's $43M one-time change-order benefit absent, analysts will re-anchor FY26 estimates toward 'core' ~25% gross margin rather than Q1's 26.3% headline, capping forward EPS revisions even after a beat. Combined with book-to-bill normalizing off record highs, tougher H2 same-store comps already flagged by management, a recent leadership reshuffle, an analyst downgrade, and heavy insider selling into a rich (~35x forward) multiple, the setup favors an initial relief pop that partially fades over the week as the market digests implicit margin/backlog deceleration rather than sustained follow-through buying.",
  "day5_confidence": "LOW"
}